Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma

Summary

This is a phase 2 study to evaluate the efficacy of single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma.

Timeline

Start

2010-09-27

Primary completion

2012-11-26

Completion

2012-11-26

Outcome

Missed primary endpoint

Stopped: “In a pre-planned interim analysis, OSI-774-205 met futility for efficacy with no safety concerns. As a result, it has been stopped.”

registry analysis (unspecified test); Erlotinib vs Etoposide; p = 0.2200; Fisher Exact NCT01032070 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Erlotinib	Small molecule	85 mg/m2	Oral
Comparator	Etoposide	Small molecule	50 mg/m2	Oral

Indications